Matches in Wikidata for { <http://www.wikidata.org/entity/Q87725699> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- Q87725699 description "article scientifique publié en 2017" @default.
- Q87725699 description "artículu científicu espublizáu en marzu de 2017" @default.
- Q87725699 description "im März 2017 veröffentlichter wissenschaftlicher Artikel" @default.
- Q87725699 description "scientific article published on 30 March 2017" @default.
- Q87725699 description "wetenschappelijk artikel" @default.
- Q87725699 description "наукова стаття, опублікована в березні 2017" @default.
- Q87725699 name "European Association of Urology and American Urological Association/Society of Urologic Oncology Guidelines on Risk Categories for Non-muscle-invasive Bladder Cancer May Lead to Overtreatment for Low-grade Ta Bladder Tumors" @default.
- Q87725699 name "European Association of Urology and American Urological Association/Society of Urologic Oncology Guidelines on Risk Categories for Non-muscle-invasive Bladder Cancer May Lead to Overtreatment for Low-grade Ta Bladder Tumors" @default.
- Q87725699 type Item @default.
- Q87725699 label "European Association of Urology and American Urological Association/Society of Urologic Oncology Guidelines on Risk Categories for Non-muscle-invasive Bladder Cancer May Lead to Overtreatment for Low-grade Ta Bladder Tumors" @default.
- Q87725699 label "European Association of Urology and American Urological Association/Society of Urologic Oncology Guidelines on Risk Categories for Non-muscle-invasive Bladder Cancer May Lead to Overtreatment for Low-grade Ta Bladder Tumors" @default.
- Q87725699 prefLabel "European Association of Urology and American Urological Association/Society of Urologic Oncology Guidelines on Risk Categories for Non-muscle-invasive Bladder Cancer May Lead to Overtreatment for Low-grade Ta Bladder Tumors" @default.
- Q87725699 prefLabel "European Association of Urology and American Urological Association/Society of Urologic Oncology Guidelines on Risk Categories for Non-muscle-invasive Bladder Cancer May Lead to Overtreatment for Low-grade Ta Bladder Tumors" @default.
- Q87725699 P1433 Q87725699-E2A8862D-72B4-422D-9137-FA81279B2D25 @default.
- Q87725699 P1476 Q87725699-2CED42DD-0F2C-4176-8073-E7BB524A9C69 @default.
- Q87725699 P2093 Q87725699-4ECE74B6-F3BA-44AB-8C43-CE9702B9F477 @default.
- Q87725699 P2093 Q87725699-AD4067FF-AEC6-4206-954E-08FB5BFBF496 @default.
- Q87725699 P2860 Q87725699-1427FC14-936D-482A-B4CE-542ACAACE73F @default.
- Q87725699 P2860 Q87725699-1C02B23D-6DCE-4A93-AB1C-565AE52766D7 @default.
- Q87725699 P2860 Q87725699-1F9C2927-1C94-4179-AFA0-B8FA5C66428A @default.
- Q87725699 P2860 Q87725699-3FF9AD24-E39A-48EB-9DDD-DF7B586FF20F @default.
- Q87725699 P2860 Q87725699-403476B1-6F4E-486C-A193-27FC27189238 @default.
- Q87725699 P2860 Q87725699-5326D94F-5E0F-43B1-A63A-AAC11E203C8D @default.
- Q87725699 P2860 Q87725699-69542C26-FAFF-431C-81A5-852E7EC11F10 @default.
- Q87725699 P2860 Q87725699-8675687B-13DA-446E-AA43-3173C5F74617 @default.
- Q87725699 P2860 Q87725699-8C1D0E17-4F29-4E72-A3F2-EA15197B0D83 @default.
- Q87725699 P2860 Q87725699-8C58A18A-0C90-447A-BAFB-4EF6BF47BAD6 @default.
- Q87725699 P2860 Q87725699-976EB302-75C5-4ABD-AD06-D47FF52904BA @default.
- Q87725699 P2860 Q87725699-9BE0C64D-A80F-4898-8EE8-F72CB8A17A66 @default.
- Q87725699 P2860 Q87725699-9EB7620D-1632-454E-BD56-1FA5CE032772 @default.
- Q87725699 P2860 Q87725699-ACDD5A13-755E-4D59-8A13-4DE96E8FA405 @default.
- Q87725699 P2860 Q87725699-BCD20757-7C47-4737-A53C-98A2B5549DAA @default.
- Q87725699 P2860 Q87725699-D05582D1-380D-4EF9-8FCE-3E4D97323E17 @default.
- Q87725699 P2860 Q87725699-D1D7AED3-A898-44FE-B309-83335BF8D47A @default.
- Q87725699 P2860 Q87725699-D40D0225-EF17-44D5-9AF1-01F41A2A5AA8 @default.
- Q87725699 P2860 Q87725699-ED6B59E5-59C2-4ACF-AF41-DFD6E719F218 @default.
- Q87725699 P304 Q87725699-2CD602CC-E8A5-4F9C-8EB4-C322C70F9B2D @default.
- Q87725699 P31 Q87725699-8395AC37-5A4D-4F51-94D1-12CC2B25FFD9 @default.
- Q87725699 P356 Q87725699-BB4C0B6D-B1E2-47A1-84B3-2B1369C10DE7 @default.
- Q87725699 P478 Q87725699-4A6BE3E1-5F8D-4112-9E06-8AE54B539AB1 @default.
- Q87725699 P577 Q87725699-C80961FD-D9E5-4632-99DA-45AA68C08C8E @default.
- Q87725699 P698 Q87725699-5A026751-0E01-46F3-BEA6-437A7D164E36 @default.
- Q87725699 P921 Q87725699-EBB3FC3A-AEF1-47F8-8AFE-0848602C9E99 @default.
- Q87725699 P356 J.UROLOGY.2017.03.034 @default.
- Q87725699 P698 28366700 @default.
- Q87725699 P1433 Q7900884 @default.
- Q87725699 P1476 "European Association of Urology and American Urological Association/Society of Urologic Oncology Guidelines on Risk Categories for Non-muscle-invasive Bladder Cancer May Lead to Overtreatment for Low-grade Ta Bladder Tumors" @default.
- Q87725699 P2093 "Mark S Soloway" @default.
- Q87725699 P2093 "Zachary Klaassen" @default.
- Q87725699 P2860 Q26852084 @default.
- Q87725699 P2860 Q36066864 @default.
- Q87725699 P2860 Q36369279 @default.
- Q87725699 P2860 Q38107307 @default.
- Q87725699 P2860 Q38133647 @default.
- Q87725699 P2860 Q38753083 @default.
- Q87725699 P2860 Q38851402 @default.
- Q87725699 P2860 Q39748314 @default.
- Q87725699 P2860 Q40831782 @default.
- Q87725699 P2860 Q41125821 @default.
- Q87725699 P2860 Q50648382 @default.
- Q87725699 P2860 Q51953901 @default.
- Q87725699 P2860 Q53237544 @default.
- Q87725699 P2860 Q73645459 @default.
- Q87725699 P2860 Q74327844 @default.
- Q87725699 P2860 Q87387266 @default.
- Q87725699 P2860 Q87711943 @default.
- Q87725699 P2860 Q88597959 @default.
- Q87725699 P2860 Q88988163 @default.
- Q87725699 P304 "14-17" @default.
- Q87725699 P31 Q13442814 @default.
- Q87725699 P356 "10.1016/J.UROLOGY.2017.03.034" @default.
- Q87725699 P478 "105" @default.
- Q87725699 P577 "2017-03-30T00:00:00Z" @default.
- Q87725699 P698 "28366700" @default.
- Q87725699 P921 Q504775 @default.